Erlotinib vs docetaxel as second-line treatment of advanced NSCLC: a real-world cost-effectiveness study.
Phase of Trial: Phase IV
Latest Information Update: 02 Nov 2011
At a glance
- Drugs Erlotinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Aug 2011 New trial record
- 07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.